

A Prospective Multicentre Real-world Assessment of the Efficacy of Danning Tablets in Alleviating Digestive Symptoms

NCT06755671

Status RECRUITING
Sponsor Shanghai Hutchison Pharmaceuticals Limited
Enrollment 4,500 participants

Key Eligibility Criteria

Inclusion (4)

- Patients between 18 and 75 years old
- Patients with at least one of the following symptoms: upper abdominal pain, bloating, loss of appetite, acid reflux or constipation
- Patients already taking Danning Tablets as part of their regular medicine treatment for dyspepsia
- Patients agree to sign the informed consent form

Exclusion (7)

- Past history or comorbidity of malignant tumor
- Comorbidity of severe systemic condition including cardiovascular, cerebrovascular, renal and hematopoietic system diseases
- Past history of abdominal surgery (post pancreatic surgery, post subtotal gastrectomy; incomplete intestinal obstruction) or mental illness, mobility difficulty (e.g. long-term bed ridden)
- Comorbidity of any unstable chronic or acute disease, which may impact the evaluation of treatment efficacy as determined by the research physician
- Pregnancy or breastfeeding
- ... and 2 more (see full listing online)

Locations (1 total)

The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, Zhejiang, China